Related to Horizon Licenses Minnesota Uni IP to Boost Rate of rAAV Gene Editing Platform

• Embryome Sciences to Enhance hESC Franchise by Gaining New Cell Lines
  
• Sanofi-Aventis Shutters 13 Clinical Programs, Gains Four from Oxford BioMedica, and Returns TroVax
  
• Tekmira to Advance Two Roche RNAi Therapies in $50.4M Deal
  
• Amarna Collaborates with Dutch Organization to Further Gene Delivery System
  
• Cellular Dynamics Gains Patent Portfolio for Using Stem Cell-Derived Cells in Drug Screening
  
• RXi Gains Rights to Advirna’s RNAi Delivery Platform
  
• GenVec Obtains $2.5M to Enhance Vector Production Technology
  
• ALS Foundations Fund Collaboration to Evaluate RXi’s Self-Delivering rxRNAs as Therapeutics
  
• Researchers Call for Greater Ethnic Diversity in Stem Cell Lines
  
• RXi Partners with University of Massachusetts Med School on RNAi Therapeutics for Ocular Disease
  
• Three Often-Used Esophageal Cancer Cell Lines Found to Be from Other Cancers
  
• Roche Allies with MGH and Harvard to Develop Stem Cell-Derived Cell Lines for Drug Discovery
  
• Investigators Come Up with Virus-Free Technique to Make Stem Cells Pluripotent
  
• Horizon and University of Torino Win $500K Grant to Develop SNP-Based Cancer Models
  
• JCOM to Use GTC Biotherapeutics’ Cell Lines for Insulin Production in Asia
  
• Sigma-Aldrich to Distribute Stemgent’s Gene Delivery Products for iPS Cells
  
• Pfizer to Assess Tekmira Technology to Deliver siRNAs in Preclinical Models
  
• Newly Established Firm Aims to Speed Development of Stable Cell Lines and Primary Cells for R&D